Personal Finance

Karyopharm Therapeutics: Pioneering Growth with Innovative Cancer Therapies

Karyopharm Therapeutics: Pioneering Growth with Innovative Cancer Therapies

Karyopharm Therapeutics, a leading commercial-stage pharmaceutical company, reported its third consecutive quarter of growth in U.S. XPOVIO® (selinexor) net product revenue, totaling $29.5 million for the third quarter of 2024. This growth is part of the company’s total revenue of $38.8 million for the same period. Karyopharm is advancing its clinical pipeline with positive changes in its Phase 3 SENTRY trial for myelofibrosis, aligning with the FDA's recent guidance to use Absolute Change in Total Symptom Score (Abs-TSS) as a co-primary endpoint.

This shift may enhance the sensitivity of evaluating new combination therapies for JAKi naïve myelofibrosis patients. These developments maintain the trial’s projected data read-out on track for the second half of 2025. The company’s financial outlook for 2024 has been adjusted, with full-year total revenue now estimated to range between $145 million and $155 million, and the U.S. XPOVIO net product revenue narrowed to between $110 million and $115 million. Research and development (R&D) and selling, general, and administrative (SG&A) expenses are projected to be between $255 million and $265 million.

In the third quarter, Karyopharm expanded patient access globally with favorable reimbursement and regulatory approvals in countries such as France, Italy, Turkiye, and South Korea. The company also reported pivotal advancements in its clinical trials across myelofibrosis, endometrial cancer, and multiple myeloma. The Phase 3 XPORT-EC-042 trial continues to enroll patients with TP53 wild-type endometrial cancer, with results anticipated in early 2026. Similarly, the XPORT-MM-031 (EMN29) trial is progressing with updated enrollment targets.

Karyopharm's current cash reserves are expected to sustain operations into early 2026, excluding obligations like the repayment of senior convertible notes due in October 2025. The company’s strategic focus includes continued disciplined expense management and leveraging its strong pipeline potential, enhancing its position in the oncology market. Karyopharm's recent global regulatory approvals and expanded access reflect its commitment to addressing high unmet needs in cancer treatment with innovative solutions like XPOVIO.

CEO Richard Paulson expressed confidence in the company's capacity to drive further growth and expand therapeutic indications, particularly in challenging fields like myelofibrosis where current treatment options are limited. As a pioneering entity in oral compounds targeting nuclear export dysregulation, Karyopharm remains at the forefront of cancer therapy innovation, with XPOVIO approved for multiple indications in various countries. The advancements in clinical trials, particularly the Phase 3 trials for myelofibrosis and endometrial cancer, hold promise for breakthrough therapies in fields with significant therapeutic gaps.